The Significance of Adjuvant Therapy for Extrahepatic Cholangiocarcinoma After Surgery

References

• Longmire WP, Mcarthur MS, Bastounis EA, et al. Carcinoma of the extrahepatic biliary tract. Ann Surg. 1973;178(3 ):333–345.4354116
   PubMed Web of Science ®Google Scholar
• de Groen PC, Gores GJ, LaRusso NF, et al. Biliary tract cancers. N Engl J Med. 1999;341(18 ):1368–1378. doi:10.1056/NEJM19991028341180710536130
   PubMed Web of Science ®Google Scholar
• Kumar JR. Advances in diagnosis and treatment of hilar cholangiocarcinoma – a review. Med Sci Monit. 2013;19:648–656. doi:10.12659/MSM.88937923921971
   PubMed Web of Science ®Google Scholar
• Sahai P, Kumar S. External radiotherapy and brachytherapy in the management of extrahepatic and intrahepatic cholangiocarcinoma: available evidence. Br J Radiol. 2017;90(1076 ):20170061. doi:10.1259/bjr.2017006128466653
   PubMed Web of Science ®Google Scholar
• Deoliveira ML, Cunningham SC, Cameron JL, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007;245(5 ):755–762. doi:10.1097/01.sla.0000251366.62632.d317457168
   PubMed Web of Science ®Google Scholar
• Nakeeb A. Cholangiocarcinoma: a spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996;224(4 ):473–475. doi:10.1097/00000658-199610000-00005
   Web of Science ®Google Scholar
• Kim BH, Kim K, Chie EK, et al. Long-term outcome of distal cholangiocarcinoma after pancreaticoduodenectomy followed by adjuvant chemoradiotherapy: a 15-year experience in a single institution. Cancer Res Treat. 2016;49(2 ):473–483. doi:10.4143/crt.2016.16627554480
   PubMed Web of Science ®Google Scholar
• Khan SA, Davidson BR, Goldin R, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut. 2002;51(Supplement 6 ):vi1–vi9. doi:10.1136/gut.51.suppl_6.vi112376491
   PubMedGoogle Scholar
• Nyberg K. Gemcitabine hydrochloride and oxaliplatin or observation in treating patients with biliary tract cancer that has been removed by surgery. Clinical Trials. gov. 2017.
   Google Scholar
• Akamatsu N, Sugawara Y, Hashimoto D. Surgical strategy for bile duct cancer: advances and current limitations. World J Clin Oncol. 2011;2(2 ):94–107. doi:10.5306/wjco.v2.i2.9421603318
   PubMedGoogle Scholar
• Nagino M, Ebata T, Yokoyama Y, et al. Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections. Ann Surg. 2012;258(1 ):129–140. doi:10.1097/SLA.0b013e3182708b57
   Web of Science ®Google Scholar
• Park SW, Park YS, Chung JB, et al. Patterns and relevant factors of tumor recurrence for extrahepatic bile duct carcinoma after radical resection. Hepato-Gastroenterol. 2004;51(60 ):1612–1618.
   PubMedGoogle Scholar
• Vogel A, Saborowski A. Cholangiocellular carcinoma. Digestion. 2017;95(3 ):181–185. doi:10.1159/00045476328288474
   PubMed Web of Science ®Google Scholar
• Benson AB 3rd, D’Angelica MI, Abbott DE, et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers (Version 1.2019). J Natl Compr Canc Netw. 2017;15(5 ):563–573. doi:10.6004/jnccn.2017.005928476736
   PubMed Web of Science ®Google Scholar
• Cereda S, Belli C, Reni M. Adjuvant treatment in biliary tract cancer: to treat or not to treat? World J Gastroenterol. 2012;18(21 ):2591–2596. doi:10.3748/wjg.v18.i21.259122690066
   PubMed Web of Science ®Google Scholar
• Brunner TB, Seufferlein T. Radiation therapy in cholangiocellular carcinomas. Best Pract Res Clin Gastroenterol. 2016;30(4 ):593–602. doi:10.1016/j.bpg.2016.08.00327644907
   PubMed Web of Science ®Google Scholar
• Ebata T, Hirano S, Konishi M, et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg. 2018;105(3 ):192–202. doi:10.1002/bjs.2018.105.issue-329405274
   PubMed Web of Science ®Google Scholar
• Edeline J, Benabdelghani M, Bertaut A, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized Phase III study. J Clin Oncol. 2019;37(8 ):658–667. doi:10.1200/JCO.18.0005030707660
   PubMed Web of Science ®Google Scholar
• Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, Phase 3 study. Lancet Oncol. 2019;20(5 ):663–673. doi:10.1016/S1470-2045(18)30915-X30922733
   PubMed Web of Science ®Google Scholar
• Murakami Y, Uemura K, Sudo T, et al. Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma. Ann Surg. 2009;250(6 ):950–956. doi:10.1097/SLA.0b013e3181b0fc8b19953713
   PubMed Web of Science ®Google Scholar
• Murakami Y, Uemura K, Sudo T, et al. Gemcitabine-based adjuvant chemotherapy improves survival after aggressive surgery for hilar cholangiocarcinoma. J Gastrointest Surg. 2009;13(8 ):1470–1479. doi:10.1007/s11605-009-0900-019421824
   PubMed Web of Science ®Google Scholar
• Wirasorn K, Ngamprasertchai T, Khuntikeo N, et al. Adjuvant chemotherapy in resectable cholangiocarcinoma patients. J Gastroenterol Hepatol. 2013;28(12 ):1885–1891. doi:10.1111/jgh.2013.28.issue-1223829232
   PubMed Web of Science ®Google Scholar
• Bergeat D, Turrini O, Courtin-Tanguy L, et al. Impact of adjuvant chemotherapy after pancreaticoduodenectomy for distal cholangiocarcinoma: a propensity score analysis from a French multicentric cohort. Langenbecks Arch Surg. 2018;403(6 ):701–709. doi:10.1007/s00423-018-1702-130112638
   PubMed Web of Science ®Google Scholar
• Kim YS, Jeong CY, Song HN, et al. The efficacy of fluoropyrimidine-based adjuvant chemotherapy on biliary tract cancer after R0 resection. Chin J Cancer. 2017;36(1 ):9. doi:10.1186/s40880-017-0182-y28086990
   PubMedGoogle Scholar
• Yin L, Xu Q, Li J, et al. The efficiency and regimen choice of adjuvant chemotherapy in biliary tract cancer A STROBE-compliant retrospective cohort study. Med. 2018;97(50 ):13570. doi:10.1097/MD.0000000000013570
   Web of Science ®Google Scholar
• Valle JW, Wasan HS, Palmer DD, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Eng J Med. 2010;362:1273–1281. doi:10.1056/NEJMoa0908721
   PubMed Web of Science ®Google Scholar
• Sharma A, Dwary AD, Mohanti BK, et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol. 2010;28(30 ):4581–4586. doi:10.1200/JCO.2010.29.360520855823
   PubMed Web of Science ®Google Scholar
• Nehls O, Klump B, Arkenau HT, et al. Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial. Br J Cancer. 2002;87(7 ):702–704. doi:10.1038/sj.bjc.660054312232749
   PubMed Web of Science ®Google Scholar
• Nehls O, Oettle H, Hartmann JT, et al. Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer. 2008;98(2 ):309–315. doi:10.1038/sj.bjc.660417818182984
   PubMed Web of Science ®Google Scholar
• Kim TW. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Ann Oncol. 2003;14(7 ):1115–1120. doi:10.1093/annonc/mdg28112853355
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Tsuji A, Morita S, et al. A phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinoma. BMC Cancer. 2006;6(1 ):121. doi:10.1186/1471-2407-6-12116677397
   PubMedGoogle Scholar
• Schoenthaler R, Phillips TL, Castro J, et al. Carcinoma of the extrahepatic bile ducts the University of California at San Francisco experience. Ann Surg. 1994;219(3 ):267–274. doi:10.1097/00000658-199403000-000068147607
   PubMed Web of Science ®Google Scholar
• Washburn WK, Lewis WD, Jenkins RL. Aggressive surgical resection for cholangiocarcinoma. Arch Surg. 1995;130(3 ):270–276. doi:10.1001/archsurg.1995.014300300400067534059
   PubMedGoogle Scholar
• Kopelson G, Galdabini J, Warshaw AL, et al. Patterns of failure after curative surgery for extra-hepatic biliary tract carcinoma: implications for adjuvant therapy. Int J Radiat Oncol Biol Phys. 1981;7(3 ):413–417. doi:10.1016/0360-3016(81)90118-87275721
   PubMed Web of Science ®Google Scholar
• Ghiassi-Nejad Z, Tarchi P, Moshier E, et al. Prognostic factors and patterns of locoregional failure after surgical resection in patients with cholangiocarcinoma without adjuvant radiation therapy: optimal field design for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 2017;99(4 ):805–811. doi:10.1016/j.ijrobp.2017.06.246729063849
   PubMed Web of Science ®Google Scholar
• Oh D, Lim DH, Heo JS, et al. The role of adjuvant radiotherapy in microscopic tumor control after extrahepatic bile duct cancer surgery. Am J Clin Oncol. 2007;30(1 ):21–25. doi:10.1097/01.coc.0000245467.97180.7817278890
   PubMed Web of Science ®Google Scholar
• Doherty MK, Knox JJ. Adjuvant therapy for resected biliary tract cancer: a review. Chin Clin Oncol. 2016;5(5 ):64. doi:10.21037/cco27701873
   PubMed Web of Science ®Google Scholar
• Sagawa N, Kondo S, Morikawa T, et al. Effectiveness of radiation therapy after surgery for hilar cholangiocarcinoma. Surg Today. 2005;35(7 ):548–552. doi:10.1007/s00595-005-2989-415976951
   PubMed Web of Science ®Google Scholar
• Vern-Gross TZ, Shivnani AT, Chen K, et al. Survival outcomes in resected extrahepatic cholangiocarcinoma: effect of adjuvant radiotherapy in a surveillance, epidemiology, and end results analysis. Int J Radiat Oncol Biol Phys. 2011;81(1 ):189–198. doi:10.1016/j.ijrobp.2010.05.00120971573
   PubMed Web of Science ®Google Scholar
• Gwak HK, Kim WC, Kim HJ, et al. Extrahepatic bile duct cancers: surgery alone versus surgery plus postoperative radiation therapy. Int J Radiat Oncol Biol Phys. 2010;78(1 ):194–198. doi:10.1016/j.ijrobp.2009.07.00319910130
   PubMed Web of Science ®Google Scholar
• Itoh H, Nishijima K, Kurosaka Y, et al. Magnitude of combination therapy of radical resection and external beam radiotherapy for patients with carcinomas of the extrahepatic bile duct and gallbladder. Dig Dis Sci. 2005;50(12 ):2231–2242. doi:10.1007/s10620-005-3040-816416167
   PubMed Web of Science ®Google Scholar
• Yang H, Zhou J, Wei X, et al. Survival outcomes and prognostic factors of extrahepatic cholangiocarcinoma patients following surgical resection: adjuvant therapy is a favorable prognostic factor. Mol Clin Oncol. 2014;2(6 ):1069–1075. doi:10.3892/mco.2014.37725279199
   PubMedGoogle Scholar
• Kim YJ, Kim K, Min SK, et al. Role of adjuvant radiotherapy for localized extrahepatic bile duct cancer. Br J Radiol. 2017;90(1071 ):20160807. doi:10.1259/bjr.2016080728118028
   PubMed Web of Science ®Google Scholar
• Krasnick BA, Jin LX, Davidson JT, et al. Adjuvant therapy is associated with improved survival after curative resection for hilar cholangiocarcinoma: a multi-institution analysis from the U.S. extrahepatic biliary malignancy consortium. J Surg Oncol. 2017;117(3 ):363–371. doi:10.1002/jso.2483629284072
   PubMed Web of Science ®Google Scholar
• Kim TH, Han SS, Park SJ, et al. Role of adjuvant chemoradiotherapy for resected extrahepatic biliary tract cancer. Int J Radiat Oncol Biol Phys. 2011;81(5 ):E853—E859. doi:10.1016/j.ijrobp.2010.12.01921497455
   PubMed Web of Science ®Google Scholar
• Han IW, Jang JY, Lee KB, et al. Clinicopathological analysis and prognosis of extrahepatic bile duct cancer with a microscopic positive ductal margin. HPB. 2014;16(6 ):575–581. doi:10.1111/hpb.1219324308425
   PubMed Web of Science ®Google Scholar
• Hoehn RS, Wima K, Ertel AE, et al. Adjuvant chemotherapy and radiation therapy is associated with improved survival for patients with extrahepatic cholangiocarcinoma. Ann Surg Oncol. 2015;22(3 ):1133–1139. doi:10.1245/s10434-015-4599-825316488
   PubMedGoogle Scholar
• Nassour I, Mokdad A, Porembka MR, et al. Adjuvant therapy is associated with improved survival in resected perihilar cholangiocarcinoma: a propensity matched study. J Am Coll Surg. 2018;25(5 ):1193–1201.
   Google Scholar
• Lee J, Kang SH, Noh O, et al. Adjuvant concurrent chemoradiation therapy in patients with microscopic residual tumor after curative resection for extrahepatic cholangiocarcinoma. Clin Transl Oncol. 2018;20(8 ):1011–1017. doi:10.1007/s12094-017-1815-y29256155
   PubMed Web of Science ®Google Scholar
• Horgan AM, Amir E, Walter T, et al. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30(16 ):1934–1940. doi:10.1200/JCO.2011.40.538122529261
   PubMed Web of Science ®Google Scholar
• Beltrán MB, Roth AD, Mentha G, et al. Adjuvant radio-chemotherapy for extrahepatic biliary tract cancers. BMC Cancer. 2011;11(1 ):267. doi:10.1186/1471-2407-11-26721702920
   PubMedGoogle Scholar
• Kim K, Chie EK, Jang JY, et al. Adjuvant chemoradiotherapy after curative resection for extrahepatic bile duct cancer: a long-term single center experience. Am J Clin Oncol. 2012;35(2 ):136. doi:10.1097/COC.0b013e318209aa2921325937
   PubMed Web of Science ®Google Scholar
• Park JH, Choi EK, Ahn SD, et al. Postoperative chemoradiotherapy for extrahepatic bile duct cancer. Int J Radiat Oncol BiolPhys. 2011;79(3 ):696–704. doi:10.1016/j.ijrobp.2009.12.031
   PubMed Web of Science ®Google Scholar
• Lim KH, Oh DY, Chie EK, et al. Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: which is better in patients with radically resected extrahepatic biliary tract cancer? A nonrandomized, single center study. BMC Cancer. 2009;9(1 ):345. doi:10.1186/1471-2407-9-34519781103
   PubMedGoogle Scholar
• Ben-Josef E, Guthrie KA, El-Khoueiry AB, et al. SWOG S0809: a phase II Intergroup Trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol. 2015;33(24 ):2617–2622. doi:10.1200/JCO.2014.60.221925964250
   PubMed Web of Science ®Google Scholar
• Jan YY, Yeh CN, Yeh TS, Chen TC. Prognostic analysis of surgical treatment of peripheral cholangiocarcinoma: two decades of experience at Chang Gung Memorial Hospital. World J Gastroenterol. 2005;11:1779–1784. doi:10.3748/wjg.v11.i12.177915793863
   PubMed Web of Science ®Google Scholar
• Kwon HJ, Kim SG, Chun JM, et al. Prognostic factors in patients with middle and distal bile duct cancers. World J Gastroenterol. 2014;20(21 ):6658–6665. doi:10.3748/wjg.v20.i21.665824914391
   PubMed Web of Science ®Google Scholar
• Jarnagin WR, Fong Y, Dematteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001;234(4 ):507–519. doi:10.1097/00000658-200110000-0001011573044
   PubMed Web of Science ®Google Scholar
• Mao Z, Guo X, Su D, et al. Prognostic factors of cholangiocarcinoma after surgical resection: a retrospective study of 293 patients. Med Sci Monit. 2015;21:2375–2381. doi:10.12659/MSM.89358626269932
   PubMed Web of Science ®Google Scholar
• Hu HJ, Mao H, Shrestha A, et al. Prognostic factors and long-term outcomes of hilar cholangiocarcinoma: a single-institution experience in China. World J Gastroenterol. 2016;22(8 ):2601–2610. doi:10.3748/wjg.v22.i8.260126937148
   PubMed Web of Science ®Google Scholar
• Lurje G, Bednarsch J, Czigany Z, et al. The prognostic role of lymphovascular invasion and lymph node metastasis in perihilar and intrahepatic cholangiocarcinoma. Eur J Surg Oncol. 2019;30411–1(19 ):S0748–7983.
   Google Scholar
• Matsuo K, Rocha FG, Ito K, et al. The blumgart preoperative staging system for hilar cholangiocarcinoma: analysis of resectability and outcomes in 380 patients. J Am Coll Surg. 2012;215(3 ):343–355. doi:10.1016/j.jamcollsurg.2012.05.02522749003
   PubMed Web of Science ®Google Scholar
• Bird NTE, Mckenna A, Dodd J, et al. Meta-analysis of prognostic factors for overall survival in patients with resected hilar cholangiocarcinoma. Br J Surg. 2018;105(11 ):1408–1416. doi:10.1002/bjs.1092129999515
   PubMed Web of Science ®Google Scholar
• Shroff RT, Kennedy EB, Bachini M, et al. Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline. J Clin Oncol. 2019;37(12 ):1015–1027. doi:10.1200/JCO.18.0217830856044
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Nagano H, Tomokuni A, et al. A prospective, randomized Phase II study of adjuvant gemcitabine versus S-1 after major hepatectomy for biliary tract cancer (KHBO 1208): Kansai hepato-biliary oncology group. Ann Surg. 2019;270(2 ):230–237. doi:10.1097/SLA.000000000000286530339627
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26 ):2509–2520. doi:10.1056/NEJMoa150059626028255
   PubMed Web of Science ®Google Scholar
• Le DT, Durham JN, Smith KN, et al. Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. Sci. 2017;357(6349 ):409–441. doi:10.1126/science.aan6733
   PubMed Web of Science ®Google Scholar